Showing 3521-3530 of 5621 results for "".
- EyePoint Announces First Patient Dosed in Phase 3 LUCIA Trial of Duravyu for Wet AMDhttps://modernod.com/news/eyepoint-announces-first-patient-dosed-in-phase-3-lucia-trial-of-duravyu-for-wet-amd/2482563/EyePoint Pharmaceuticals announced that the first patient has been dosed in the LUCIA trial. This is the second global phase 3 clinical trial evaluating Duravyu (formerly EYP-1901), a sustained-delivery therapy for treating wet age-related macular degeneration (AMD). Duravyu is an inves
- Nicole Skibinski Appointed Chief Executive Officer of Fluorescene Mediahttps://modernod.com/news/nicole-skibinski-appointed-chief-executive-officer-of-fluorescene-media/2482562/Nicole Skibinski was appointed Chief Executive Officer of Fluorescene Media, which aims to help optometry professionals connect, learn, and thrive. Ms. Skibinski has more than 20 years of leadership in the eye care and health care industries, with experience in
- Nidek Launches NP-T Preloaded Toric IOL Injection Systemhttps://modernod.com/news/nidek-launches-np-t-preloaded-toric-iol-injection-system/2482560/Nidek announced the international launch of its NP-T Preloaded Toric IOL Injection System. Previously available exclusively in Japan, the system is now available globally. The NP-T system is designed to combine precision engineering with user-friendly design, featuring a prelo
- FDA Clears Novoxel's Tixel for the Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/fda-clears-novoxels-tixel-for-the-treatment-of-meibomian-gland-dysfunction/2482559/Isreal-based Novoxel announced the the FDA clearance of its Tixel device for application of localized heat and pressure for patients with evaporative dry eye due to meibomian gland dysfunction (MGD). The Tixel systems use proprietary Thermo-Mechanical Actio
- Johnson & Johnson Appoints Shawn Millerick President, Vision Care, Americashttps://modernod.com/news/johnson-johnson-appoints-shawn-millerick-president-vision-care-americas/2482556/Johnson & Johnsonhas announced the appointment of Shawn Millerick as President, Vision Care, Americas, effective November 11, 2024. Mr. Millerick will be responsible for defining strategy and driving growth for Johnson & Johnson’s Vision Care portfolio in North Americ
- Alcon Expands TOTAL30 for Astigmatism Offerings with New Parametershttps://modernod.com/news/alcon-expands-total30-for-astigmatism-offerings-with-new-parameters-to-enhance-comfort-and-accessibility/2482553/Alcon announced the availability of expanded parameters for TOTAL30 for Astigmatism. As the first and only monthly replacement Water Gradient toric contact lens, TOTAL30 is designed to deliver a
- Melt Pharmaceuticals Announces Positive Phase 3 Trial Results for MELT-300 Sedation Solutionhttps://modernod.com/news/melt-pharmaceuticals-announces-positive-phase-3-trial-results-for-melt-300-sedation-solution/2482552/Melt Pharmaceuticals announced positive topline results from its pivotal phase 3 trial of MELT-300. This novel, non-intravenous, non-opioid tablet is designed to provide effective sedation during cataract surgery. The phase 3 study, conducted under a Special Protocol Assessment (SPA) ag
- Ocugen Reports Positive Preliminary Data from OCU410 Trial for Geographic Atrophyhttps://modernod.com/news/ocugen-reports-positive-preliminary-data-from-ocu410-trial-for-geographic-atrophy/2482550/Ocugen announced encouraging preliminary results from the phase 1 portion of its phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The trial, which includes nine patients across three dose cohorts, revealed promis
- Adverum Announces Postive LUNA Phase 2 and OPTIC Long-Term Data on Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-announces-postive-luna-phase-2-and-optic-long-term-data-on-gene-therapy-for-wet-amd/2482546/Adverum Biotechnologies has released 52-week topline results from its phase 2 LUNA trial and new 4-year follow-up data from the OPTIC phase 1/2 study on its wet AMD gene therapy candidate Ixo-vec (AAV.7m8-aflibercept). “We are thrilled to report 52-week LUNA d
- Samsung Bioepis and Biogen Announce EC Approval of Eylea Biosimilar Opuvizhttps://modernod.com/news/samsung-bioepis-and-biogen-announce-ec-approval-of-eylea-biosimilar-opuviz/2482545/Samsung Bioepis and Biogen jointly announced that the European Commission (EC) has granted approval for Opuviz 40 mg/mL for injection in a vial. The biosimilar, also known as SB15, references the established treatment Eylea (aflibercept) and was developed by Samsung Bioepis. T